At Memorial Sloan-Kettering we offer a variety of clinical trials for people with mesothelioma. While some studies are looking for genetic factors that predispose people to the disease, others are exploring ways to combine chemotherapy, surgery, and radiation to optimize outcomes. We are also conducting studies testing novel therapies.
Our high volume of patients with mesothelioma enables us to be leaders in running trials for this rare tumor type. For example, our medical oncologists led the largest international randomized trial in mesothelioma testing a drug called vorinostat, which was developed at Memorial Sloan-Kettering. Although this trial failed to show a benefit for mesothelioma, other types of drugs are now being developed.
Our mesothelioma treatment team is experienced in selecting people who are most likely to benefit from a particular therapy, and we can help guide you through the process of enrolling in the most appropriate clinical trial.
Here you can find a continually updated listing of Memorial Sloan-Kettering's current clinical trials for mesothelioma. To learn more about a study, choose from the list below.
| Title | Investigator |
|---|---|
|
A Phase I Study of GL-ONC1 for Treating Malignant Pleural Effusion [Protocol 12-169] |
Rusch, Valerie, MD |
|
A Phase II Study of Tremelimumab versus Placebo for Previously Treated Inoperable Mesothelioma [Protocol 13-092] |
Krug, Lee, MD |
|
A Phase II Study of WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma [Protocol 10-134] |
Krug, Lee, MD |
|
A Phase II Toxicity Study Using Chemotherapy Followed By Intensity Modulated Radiation Therapy to the Pleura in Patients with Locally Advanced Unresectable Malignant Pleural Mesothelioma [Protocol 08-053] |
Krug, Lee, MD |
|
A Survey of Psychosocial Needs and Exploration of Online Support for Patients with Pleural Mesothelioma [Protocol 11-066] |
Key, Richard, MD |
